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Abstract Although Singapore is in an endemic region for hepatitis B infection, the hepatitis B carriage rate of 56/% is relatively low. The highest positivity rates for hepatitis B surface antigen (HBsAg) (50) 17 (35) Cirrhosis (%) 21 (15) 12 (14) 9 (19) Total (%/,) 125 (100) 87 (64) 48 (36)
presentation and all of these died within two years of diagnosis. Chemotherapy did not seem to improve survival. Ten patients underwent successful resections, but two of them died one year later -one from liver failure and the other from disease recurrence. Four patients were still alive and had been followed up for a mean duration of 18 months (range 7-34 months) when the study was published.
Because of the unresectable nature of the lesion at clinical presentation, attempts have been made at early detection of HCC in high risk patients by frequent measurements of serum et fetoprotein and liver ultrasound, and this has resulted in increased numbers of resectable tumours. It is, however, an expensive measure and may not be cost effective.19 20 
Treatment
The aim of treatment of patients with chronic HBV infection is to eliminate viral replication and hence to prevent liver damage. Elimination of HBV with successful treatment is rare in this part of the world. Hepatitis B vaccination is now being recommended for the following groups of people: health care workers, inmates of homes for the intellectually impaired, and people at risk from direct contact with infected people. Due to the initial high cost of the vaccine, studies using reduced doses ofvaccine were performed both in infants and adults. These studies showed that the reduced doses were as effective as the manufacturer's recommended dose. 30 31 Antibody values, however, were much lower than those achieved using the manufacturer's recommended regimen. Despite this, persistence of antibodies was similar to that achieved using the recommended doses. 29 32 No local figures are available on the number of people vaccinated with the hepatitis B vaccine. In view of the prevalence of hepatitis B infection locally, it is recommended that hepatitis B serology be performed before vaccination is given. Vaccinating a carrier is harmless but wasteful and gives a false sense of security, although a recent study in France has shown that vaccination of such individuals may have therapeutic implications.33 On the one hand, vaccination would boost anti-HBs values in those already immune. On the other hand, however, vaccination is been shown to give rise to vaccine escape mutants. 34 35 In 1990, Carmen and colleagues reported a point mutation in residue 145 (predicting a change from glycine to arginine) in the second loop of the 'a' determinant of the surface genome in an infant from southern Italy.34 Four similar cases were later identified in Singapore and Japan. 35 All these infants were born of HBeAg positive mothers and all had vaccination together with immunoprophylaxis. Horizontal transmission of these mutants has not been proved. Figure 3 shows the impact ofhepatitis B vaccination on the incidence of chronic hepatitis B infection in Singapore. The number of acute cases has fallen by 60% between 1989 and 1995.3 The impact of vaccination on the incidence of HCC will not be evident until about 20 years' time.
Conclusion
Hepatitis B vaccination is preventing mother to child transmission of hepatitis B infection S16 and stemming the source of the carrier pool locally. The problem of the longterm complications of chronic hepatitis B infectionnotably cirrhosis and HCC -still needs to be tackled. To date, the only effective treatment for chronic hepatitis B infection is alpha interferon, and this is appropriate in only about 30-40% of chronic hepatitis B infections locally. Clinical trials using nucleoside analogues seem promising. Both these agents reduce HBV replication and therefore the infectivity of the affected person and the disease activity in the liver. Complete elimination of HBV is not always possible with the currently available therapeutic agents. New classes of drugs are urgently needed, especially for those patients in the early stages of the disease.
